Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Rhea-AI Summary
Protagonist Therapeutics (NASDAQ:PTGX) announced that Dinesh V. Patel, Ph.D., President and CEO will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 8:15 AM PST.
The company will hold one-on-one investor meetings during the conference. A live webcast is available at the provided J.P. Morgan link, and a replay will be posted on Protagonist's Investor Relations Events and Presentations webpage for one year following the event. Investors seeking meetings should contact their J.P. Morgan representative.
Positive
- None.
Negative
- None.
News Market Reaction – PTGX
In the Jan 7 session, PTGX gained 0.09%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | NDA submission | Positive | -3.4% | NDA filed for rusfertide in PV with positive VERIFY Phase 3 data. |
| Nov 06 | Earnings & update | Positive | -0.3% | Q3 2025 results and broad pipeline milestones with strong cash runway. |
| Nov 03 | Conference data | Positive | +0.7% | Multiple rusfertide presentations at ASH highlighting Phase 3 and extension data. |
| Oct 27 | Clinical data | Positive | +0.5% | New icotrokinra data in UC and psoriasis supporting ongoing ICONIC programs. |
| Oct 07 | Clinical data | Positive | +2.1% | Phase 2b ANTHEM-UC results showing strong efficacy and favorable safety. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive updates (NDA filings, strong trial data, solid cash) have sometimes seen muted or negative next-day price reactions.
Over the past few months, Protagonist reported multiple key milestones, including new icotrokinra ulcerative colitis data on Oct 7, 2025 and broader psoriasis/UC results on Oct 27, 2025, both with favorable efficacy and safety signals. Rusfertide data were showcased at ASH in early December per the Nov 3, 2025 announcement, leading into a full NDA submission on Jan 5, 2026. Today’s J.P. Morgan conference participation fits into this ongoing investor and partner visibility campaign rather than introducing new clinical or regulatory data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisco, CA. The Company will also participate in one-on-one meetings.
44th Annual J.P. Morgan Healthcare Conference - January 12-15, 2026
Format: Company Presentation
Day/Time: Tuesday, January 13 at 8:15 AM PST
If you are interested in meeting with the Protagonist team during the conference, please reach out to your J.P. Morgan representative.
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July, and an NDA for rusfertide submitted in December 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R"), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire